Top 50 of 132 AI-discovered patents by relevance.
Composition (30) 95/100 10669338 Grant: 2020-06-02 | Exp: 2040-05-28 Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1▼ 95/100 10954305 Grant: 2021-03-23 | Exp: 2041-03-18 Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers▼ 95/100 11052156 Grant: 2021-07-06 | Exp: 2041-07-01 Antibody-drug conjugates and uses thereof▼ 95/100 12310958 Grant: 2025-05-27 | Exp: 2045-05-22 Antibody-drug conjugates and uses thereof▼ 92/100 10034950 Grant: 2018-07-31 | Exp: 2038-07-26 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 92/100 9475884 Grant: 2016-10-25 | Exp: 2036-10-20 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 92/100 9931417 Grant: 2018-04-03 | Exp: 2038-03-29 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 92/100 10653793 Grant: 2020-05-19 | Exp: 2040-05-14 Antibody-drug conjugates and uses thereof▼ 92/100 11116846 Grant: 2021-09-14 | Exp: 2041-09-09 Antibody-drug conjugates and uses thereof▼ 92/100 10143756 Grant: 2018-12-04 | Exp: 2038-11-29 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 92/100 10682347 Grant: 2020-06-16 | Exp: 2040-06-11 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 92/100 12397063 Grant: 2025-08-26 | Exp: 2045-08-21 Antibody-conjugates for targeting of tumours expressing Trop-2▼ 90/100 8268317 Grant: 2012-09-18 | Exp: 2032-09-13 Camptothecin-binding moiety conjugates▼ 90/100 10751420 Grant: 2020-08-25 | Exp: 2040-08-20 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 90/100 10849986 Grant: 2020-12-01 | Exp: 2040-11-26 Antibody-drug conjugates and uses thereof▼ 88/100 9375489 Grant: 2016-06-28 | Exp: 2036-06-23 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 88/100 12257281 Grant: 2025-03-25 | Exp: 2045-03-20 Hydrophilic antibody-drug conjugates▼ 88/100 11944689 Grant: 2024-04-02 | Exp: 2044-03-28 Drug conjugates with self-stabilizing linkers having improved physiochemical properties▼ 85/100 9107960 Grant: 2015-08-18 | Exp: 2035-08-13 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 85/100 9388237 Grant: 2016-07-12 | Exp: 2036-07-07 Immunoconjugates with an intracellularly-cleavable linkage▼ 85/100 9833511 Grant: 2017-12-05 | Exp: 2037-11-30 RS7 antibodies▼ 85/100 8617558 Grant: 2013-12-31 | Exp: 2033-12-26 Camptothecin-binding moiety conjugates▼ 85/100 9745380 Grant: 2017-08-29 | Exp: 2037-08-24 RS7 antibodies▼ 85/100 7829531 Grant: 2010-11-09 | Exp: 2030-11-04 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease▼ 85/100 7585491 Grant: 2009-09-08 | Exp: 2029-09-03 Immunoconjugates with an intracellularly-cleavable linkage▼ 85/100 9522194 Grant: 2016-12-20 | Exp: 2036-12-15 Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus▼ 85/100 9629926 Grant: 2017-04-25 | Exp: 2037-04-20 Antibody-SN-38 immunoconjugates with a CL2A linker▼ 85/100 9458242 Grant: 2016-10-04 | Exp: 2036-09-29 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 85/100 11066468 Grant: 2021-07-20 | Exp: 2041-07-15 Immunoconjugates with an intracellularly-cleavable linkage▼ 78/100 12371507 Grant: 2025-07-29 | Exp: 2045-07-24 CDCP1 antibodies and antibody drug conjugates▼
Method of Use (19) 98/100 12364761 Grant: 2025-07-22 | Exp: 2045-07-17 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 98/100 10130718 Grant: 2018-11-20 | Exp: 2038-11-15 Antibody-drug conjugates and uses thereof▼ 95/100 10266605 Grant: 2019-04-23 | Exp: 2039-04-18 Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors▼ 95/100 10799597 Grant: 2020-10-13 | Exp: 2040-10-08 Subcutaneous administration of antibody-drug conjugates for cancer therapy▼ 95/100 11052081 Grant: 2021-07-06 | Exp: 2041-07-01 Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)▼ 95/100 10918721 Grant: 2021-02-16 | Exp: 2041-02-11 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 95/100 11439620 Grant: 2022-09-13 | Exp: 2042-09-08 Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors▼ 95/100 11192955 Grant: 2021-12-07 | Exp: 2041-12-02 Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors▼ 95/100 10413539 Grant: 2019-09-17 | Exp: 2039-09-12 Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)▼ 94/100 10137196 Grant: 2018-11-27 | Exp: 2038-11-22 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 92/100 10130626 Grant: 2018-11-20 | Exp: 2038-11-15 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 92/100 10918734 Grant: 2021-02-16 | Exp: 2041-02-11 Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51▼ 92/100 10744129 Grant: 2020-08-18 | Exp: 2040-08-13 Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2▼ 92/100 10195175 Grant: 2019-02-05 | Exp: 2039-01-31 Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors▼ 92/100 12251441 Grant: 2025-03-18 | Exp: 2045-03-13 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 90/100 11541047 Grant: 2023-01-03 | Exp: 2042-12-29 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 86/100 9481732 Grant: 2016-11-01 | Exp: 2036-10-27 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼ 85/100 9707302 Grant: 2017-07-18 | Exp: 2037-07-13 Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer▼ 82/100 9226973 Grant: 2016-01-05 | Exp: 2035-12-31 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity▼
Manufacturing (1) 85/100 11712480 Grant: 2023-08-01 | Exp: 2043-07-27 Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates▼